Automate Your Wheel Strategy on MCK
With Tiblio's Option Bot, you can configure your own wheel strategy including MCK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MCK
- Rev/Share 2867.8195
- Book/Share -13.5304
- PB -43.2067
- Debt/Equity -3.5632
- CurrentRatio 0.8993
- ROIC 0.2659
- MktCap 89398788960.0
- FreeCF/Share 44.8163
- PFCF 15.9328
- PE 27.1959
- Debt/Assets 0.0983
- DivYield 0.0048
- ROE -1.3273
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | MCK | Mizuho | -- | Neutral | -- | $630 | Dec. 4, 2024 |
| Downgrade | MCK | Robert W. Baird | Outperform | Neutral | $603 | $531 | Sept. 24, 2024 |
| Reiterated | MCK | Leerink Partners | -- | Outperform | $670 | $665 | Sept. 5, 2024 |
News
MCK Stock Up on Q4 Earnings Beat & Potential Surgical Biz Spin-Off
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
McKesson's fourth-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
Read More
Brokers Suggest Investing in McKesson (MCK): Read This Before Placing a Bet
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
MCK Stock Up 24% YTD: Should You Buy, Hold or Sell Before Q4 Earnings?
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
McKesson's fourth-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
Read More
McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
3 Safe Dividend Stocks as Investors Seek to Reset Diversification
Published: April 11, 2025 by: MarketBeat
Sentiment: Positive
Over the last three years, diversification has fallen out of fashion. When investors can make 20% or higher returns in technology stocks and even more from the Magnificent 7, the idea of investing in low-growth dividend stocks loses some appeal.
Read More
McKesson Gets Drugs to Patients. Buy the Stock for Healthy Returns.
Published: April 03, 2025 by: Barrons
Sentiment: Positive
An aging U.S. population is increasing the demand for medication, and this company delivers.
Read More
McKesson: Immune To Weak Economy And Tariffs; Top Idea In 2025
Published: March 25, 2025 by: Seeking Alpha
Sentiment: Neutral
I maintain a 'Strong Buy' rating on McKesson with a fair value of $723 per share due to its robust oncology network and strong growth prospects. McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability, making it a reliable investment amid economic uncertainties. The company's GLP-1 and oncology franchises are key growth drivers, with GLP-1 revenue growing 45% year-over-year and oncology patient visits increasing steadily.
Read More
McKesson Corporation (MCK) TD Cowen 45th Annual Healthcare Conference Transcript
Published: March 04, 2025 by: Seeking Alpha
Sentiment: Neutral
McKesson Corporation (NYSE:MCK ) TD Cowen 45th Annual Healthcare Conference Call March 4, 2025 9:50 AM ET Company Participants Britt Vitalone – Executive Vice President and Chief Financial Officer Conference Call Participants Unidentified Analyst Good morning. Thanks for joining us for the next session here at the TD Cowen Healthcare Conference and very pleased to have with us McKesson.
Read More
Should You Buy, Hold or Sell MCK Stock Following Robust Q3 Earnings?
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
McKesson MCK delivered an 18% increase in revenues ($95.3 billion) and a 16% rise in adjusted operating profit during the third quarter of fiscal 2025 despite ongoing macroeconomic challenges. The company also raised its full-year guidance.
Read More
About McKesson Corporation (MCK)
- IPO Date 1994-11-10
- Website https://www.mckesson.com
- Industry Medical - Distribution
- CEO Brian S. Tyler
- Employees 44000